Q4 EPS Estimates for 908 Devices Reduced by Leerink Partnrs

908 Devices Inc. (NASDAQ:MASS - Free Report) - Leerink Partnrs dropped their Q4 2025 earnings per share (EPS) estimates for 908 Devices in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.25) for the quarter, down from their previous forecast of ($0.24). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices' FY2026 earnings at ($1.10) EPS.

A number of other analysts also recently issued reports on the stock. Stifel Nicolaus lowered their price target on shares of 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Leerink Partners restated a "market perform" rating and set a $4.00 target price (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a report on Saturday, January 18th. Finally, Stephens reissued an "overweight" rating and issued a $6.00 price objective on shares of 908 Devices in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, 908 Devices has a consensus rating of "Moderate Buy" and a consensus target price of $5.33.

908 Devices Stock Down 1.1 %

Shares of NASDAQ MASS traded down $0.03 during midday trading on Thursday, reaching $2.78. 490,268 shares of the stock were exchanged, compared to its average volume of 1,494,969. The firm has a market cap of $96.80 million, a price-to-earnings ratio of -1.57 and a beta of 0.96. The firm has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $3.46. 908 Devices has a twelve month low of $1.81 and a twelve month high of $8.50.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MASS. Bank of New York Mellon Corp raised its stake in 908 Devices by 6.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 69,550 shares of the company's stock valued at $358,000 after purchasing an additional 4,212 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of 908 Devices by 18.6% during the second quarter. American Century Companies Inc. now owns 33,718 shares of the company's stock worth $174,000 after buying an additional 5,295 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of 908 Devices by 88.3% in the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company's stock valued at $1,263,000 after buying an additional 114,987 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of 908 Devices by 79.4% in the second quarter. Renaissance Technologies LLC now owns 195,500 shares of the company's stock worth $1,007,000 after buying an additional 86,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of 908 Devices in the second quarter worth about $229,000. Institutional investors and hedge funds own 88.06% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.